适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 103
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1/2 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell LymphomasRelapsed/refractory (R/R) B-cell and T-cell lymphomasMedDRA version: 20.0Level: PTClassification code: 10003899Term: B-cell lymphoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2022-502299-21-00Step Pharma189
进行中（未招募）
1 期
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864Advanced MelanomaCTIS2023-507377-17-00Microbiotica Limited40
招募中
1 期
A Study of SGN-BB228 in Advanced Melanoma and Other Solid TumorsCTIS2022-502348-11-00Seagen Inc.275
进行中（未招募）
1 期
First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor ß in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])Metabolic dysfunction-associated steatotic liver disease, Crohn’s disease, Primary Sclerosing CholangitisMedDRA version: 24.1Level: LLTClassification code: 10086076Term: Fibrostenotic Crohn´s disease Class: 100000004848MedDRA version: 20.0Level: PTClassification code: 10076331Term: Steatohepatitis Class: 100000004871MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-506555-15-00Antaros Medical AB30
招募中
1 期
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid TumorsCTIS2023-505576-29-00Centessa Pharmaceuticals UK Limited180